Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Medical Malpractice Law & StrategyLJN NewslettersNewsSections

Drug & Device News

By ALM Staff | Law Journal Newsletters |
November 28, 2011

To Combat Drug Shortages, President Orders Changes

President Obama issued an executive order on Oct. 31 directing the FDA to take three steps to lessen the incidence of shortages of important drugs. The agency was instructed to: 1) report potential shortages of important prescription drugs; 2) speed up the review of applications to manufacture these drugs; and 3) report suspicions of collusion or price gouging concerning these drugs to the U.S. Department of Justice (DOJ). Although legislation dealing with the same concerns prompting the executive order has been pending in Congress since early this year, little has been done with the proposed measures. At the same time, a record number of drug shortages have been reported this year, with patients being required to try less effective drugs because the recommended ones simply are not available. Some of the blame for these shortages goes to supply disruptions that occur after safety issues arise at manufacturing plants, shutting down production until satisfactory changes can be made. Other shortages may be caused by ingredient supply-line problems

This premium content is locked for LJN Newsletters subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
The DOJ's Corporate Enforcement Policy: One Year Later Image

The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.

The DOJ's New Parameters for Evaluating Corporate Compliance Programs Image

The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.

Use of Deferred Prosecution Agreements In White Collar Investigations Image

This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.

Compliance Officers: Recent Regulatory Guidance and Enforcement Actions and Mitigating the Risk of Personal Liability Image

This article explores legal developments over the past year that may impact compliance officer personal liability.

Bankruptcy Sales: Finding a Diamond In the Rough Image

There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.